← Back to Search

Ketamine for Mental Illness

Phase 1
Recruiting
Led By Karl Deisseroth, MD, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age >18 years old
Female participants are expected to use an effective method of birth control throughout the study which includes: hormonal methods (birth control pills, patches, injections, vaginal ring or implants), barrier methods (condom or diaphragm) used with spermicide, intrauterine device (IUD), or abstinence (no sex)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 week
Awards & highlights

Study Summary

This trial explores how ketamine affects the brain to cause dissociation, a state of mental detachment.

Who is the study for?
This trial is for adults over 18 who are inpatients at Stanford Medical Center's clinical neuro units. Women must use effective birth control during the study, including hormonal methods, barrier methods with spermicide, IUDs, or abstinence.Check my eligibility
What is being tested?
The study aims to understand how ketamine hydrochloride affects brain function related to dissociative symptoms often seen in mental illness and disruptive behaviors.See study design
What are the potential side effects?
Ketamine may cause side effects such as feelings of detachment from reality (dissociation), changes in perception, dizziness, nausea, increased heart rate and blood pressure.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I am using or will use effective birth control during the study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 week
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 week for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with dissociative events during ketamine infusion as assessed by CADSS (Clinician-Administered Dissociative State Scale)

Side effects data

From 2020 Phase 4 trial • 75 Patients • NCT03156504
1%
Lightheadedness with low blood pressure
1%
Pump Malfunction
1%
PTSD
100%
80%
60%
40%
20%
0%
Study treatment Arm
Ketamine

Trial Design

1Treatment groups
Experimental Treatment
Group I: KetamineExperimental Treatment1 Intervention
Study participants will receive 0.5mg/kg of ketamine - one single infusion
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ketamine Hydrochloride
2018
Completed Phase 4
~1000

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,395 Previous Clinical Trials
17,341,230 Total Patients Enrolled
Karl Deisseroth, MD, PhDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current cohort size for this research endeavor?

"Absolutely, the information posted on clinicaltrials.gov indicates that this trial is currently searching for suitable participants. The study was initially advertised on October 5th 2023 and recently revised November 21st 2023; it aims to recruit 120 patients from 1 site."

Answered by AI

Can you explain the potential risks associated with administering Ketamine?

"The safety of Ketamine is rated 1, as this trial has yet to collect enough data to support its efficacy and there are few studies available that demonstrate its security."

Answered by AI

Are new participants being enrolled for this trial?

"According to the information found on clinicaltrials.gov, this medical trial is seeking participants and was first made available on October 5th 2023 with its latest update occurring on November 21st of that same year."

Answered by AI

Who else is applying?

What site did they apply to?
Stanford University
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

Recent research and studies
clinicaltrials.govStudy
HNC: Human Neural Circuits Electrophysiology During Cognition
Karl Deisseroth 2023. "HNC: Human Neural Circuits Electrophysiology During Cognition". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05962424.
~80 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top